Should You Buy NRC Health Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, NRC Health (NRC) carries a solid Quality of Company rating of 7.3/10. Trading at $21.48, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 1 of 11 CirclFi valuation models project upside for NRC Health (NRC) at $21.48 — the model consensus leans bearish, with a Quality Score of 7.3/10 and Value-Trap risk of 8/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $21.91 (+2.0% upside)
- According to the CirclFi Quality of Company (QOC) framework, NRC Health's quality score of 7.3/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation.
The Bear Case
Target: $0.98 (-95.5%)
- According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model sees the stock as overvalued with a fair value of $0.98 (-95.5%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +97.5% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
The Bottom Line
Our valuation engine sends a clear cautionary signal on NRC Health at $21.48. 9/11 models flag overvaluation, composite fair value sits at $10.65 (-50.4%), and the risk-reward profile appears unfavorable. Quality at 7.3/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. NRC Health's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy NRC stock right now?
Based on CirclFi's multi-model analysis, 1 of 11 models see upside for NRC at $21.48. The models are divided, which means the investment case depends heavily on your assumptions about NRC Health's future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in NRC Health?
Key risks include: wide model disagreement (2145% spread), signaling high uncertainty; general market and sector-specific risks affecting Services-Commercial Physical & Biological Research companies. Always diversify and consult a financial advisor.
How does NRC compare to its competitors?
Among Services-Commercial Physical & Biological Research peers, NRC holds a Quality Score of 7.3/10. Comparable companies include MEDP (QOC 10.0), IQV (QOC 8.7), CRL (QOC 8.5). The relative ranking helps investors identify whether NRC offers better fundamental quality than alternatives in the same sector.
Is NRC a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. NRC's Quality Score of 7.3/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy NRC at?
CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $0.98 to $21.91. At $21.48, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for NRC.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad